Forschungszentrum für Immuntherapie (FZI)
Forschungsschwerpunkt / Johannes Gutenberg-Universität Mainz
Shahneh, F.; Johann, K.; Bohn, T. et al.
Suppression of cAMP formation by inhibitor-loaded polypept(o) ide micelles inhibits melanoma growth by preserving an inflammatory myeloid cell phenotypeEXPERIMENTAL DERMATOLOGY. Bd. 31. H. 2. 2022 S. E48-E48
Stickdorn, Judith; Stein, Lara; Arnold-Schild, Danielle et al.
Systemically Administered TLR7/8 Agonist and Antigen-Conjugated Nanogels Govern Immune Responses against TumorsACS NANO. Bd. 16. H. 3. 2022 S. 4426-4443
Brummer, Tobias; Zipp, Frauke; Bittner, Stefan
T cell-neuron interaction in inflammatory and progressive multiple sclerosis biologyCURRENT OPINION IN NEUROBIOLOGY. Bd. 75. 2022
Rampoldi, Francesca; Donato, Elisa; Ullrich, Leon et al.
T cells license immature B cells to produce a broad range of polyreactive antibodiesCELL REPORTS. Bd. 39. H. 8. 2022
Benakis, Corinne; Simats, Alba; Tritschler, Sophie et al.
T cells modulate the microglial response to brain ischemiaELIFE. Bd. 11. 2022
Arendholz, L. T.; Schwingen, J.; Freund, L. et al.
The G-protein coupled receptor EBI2 is involved in the pathogenesis of murine TNCB-induced contact hypersensitivityEXPERIMENTAL DERMATOLOGY. Bd. 31. H. 2. 2022 S. E53-E54
Schäfer, MKE
The role of regulatory T cells in traumatic brain injuryCellular, Molecular, Physiological, and Behavioral Aspects of Traumatic Brain Injury. Elsevier 2022
Bock, S.; Ruck, T.; Cengiz, D. et al.
The two-pore-domain potassium channel K(2P)18.1 mediates translation of T cell receptor signals during thymic Treg developmentMULTIPLE SCLEROSIS JOURNAL. Bd. 28. H. 3_SUPPL. 2022 S. 77-78
Ziemssen, T.; Ettle, B.; Groth, M. et al.
Tracking the immune response to SARS-CoV-2 mRNA vaccines in ofatumumab treated RMS patients in a multicenter studyEUROPEAN JOURNAL OF NEUROLOGY. Bd. 29. 2022 S. 151-151
Ziemssen, T.; Schlegel, E.; Groth, M. et al.
Tracking the immune response to SARS-CoV-2 mRNA vaccines in ofatumumab treated RMS patients in a multicenter study (KYRIOS trial)MULTIPLE SCLEROSIS JOURNAL. Bd. 28. H. 3_SUPPL. 2022 S. 625-625